-
Article
Open AccessHow to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?
In patients with multiple endocrine neoplasia type 1 syndrome (MEN 1) and Zollinger–Ellison syndrome (ZES), gastrinomas arise from the duodenum, about 60% are multiple, and about 15% of patients have coexistin...
-
Article
Open AccessNationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan
Neuroendocrine neoplasm (NEN) is a comparatively rare tumor that has been considered indolent. Due to these characteristics, detailed epidemiological data have not been analyzed in Japan. To elucidate the pres...
-
Article
Open AccessJNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis
Neuroendocrine neoplasms (NENs) are rare neoplasms that occur in various organs and present with diverse clinical manifestations. Pathological classification is important in the diagnosis of NENs. Treatment st...
-
Article
Open AccessO6-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms
Streptozocin (STZ) is used for treating both pancreatic (PanNET) and gastrointestinal (GI-NET) neuroendocrine tumors but its therapeutic efficacy is relatively low in GI-NETs. Therefore, it has become pivotal ...
-
Article
Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
In the original publication of this article, the license subtype should be CC BY and not CC BY-NC.
-
Article
Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy
Streptozocin (STZ) is a key agent for treating advanced pancreatic neuroendocrine tumors (pNET). Most STZ regimens for pNET are daily and also include 5-fluorouracil (5FU), whereas STZ monotherapy and weekly r...
-
Chapter
Molecular Targeted Therapy for Gastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are generally considered rare tumor. According to the recent studies, the number of patients had been increasing and frequently diagnosed as advanced ...
-
Article
Open AccessA primary hepatic gastrinoma accompanied by hyperplasia of multi-nodular Brunner’s glands
Primary hepatic gastrinoma causing severe ulcerogenic syndrome is extremely rare. Herein, we report a case of primary hepatic gastrinoma accompanied by hyperplasia of multi-nodular Brunner’s glands in a patien...
-
Article
Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan
Several new developments have occurred in the field of pancreatic neuroendocrine neoplasm (PNEN) recently in Japan. First, the utility of chromogranin A (CgA), useful for the diagnosis and monitoring of the tr...
-
Article
Open AccessStreptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan
Neuroendocrine tumors (NETs) are believed to be relatively rare and to follow a generally indolent course. However, liver metastases are common in NET patients and the outcome of NET liver metastasis is poor. ...
-
Article
Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis
Although neuroendocrine tumors (NETs) are rare, the number of patients with NET is increasing. However, in Japan, there have been no epidemiological studies on NET since 2005; thus, the prevalence of NET rema...
-
Article
Open AccessPhase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
Background. Pancreatic neuroendocrine tumors (NETs) are rare but are frequently diagnosed at advanced stages and require systemic therapy. Patients and methods. This multicenter, open-label, phase II study evalu...
-
Article
Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited endocrine tumor syndrome characterized by tumor development in various endocrine organs such as the parathyroid, endocrine pancre...
-
Article
Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan
There have been few epidemiological studies on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Japan.
-
Article
VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome
We report a case of VIPoma in a 72-year-old female patient who presented with excessive diarrhea, severe hypokalemia, and acidemia. She had been referred to our hospital three times because of severe diarrhea....
-
Chapter
Gastrinoma
In 1955, Zollinger and Ellison described two patients in whom jejunal peptic ulcers recurred, successively resistant to conventional ulcer operations including vagotomy and a few distal gastrectomies until a t...
-
Article
Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: Final results of a randomized multi-institutional trial
Although the outcome of surgery for locally advanced pancreatic cancer remains poor, it is improving, with 5-year survival up to about 10% in Japan. The preliminary results of our multi-institutional randomize...
-
Article
Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors
We conducted a nationwide survey to estimate the incidence of neuroendocrine gastrointestinal tumors (NETs) newly diagnosed in Japan from 2002 through 2004.
-
Article
Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas
Genome-wide expression profiling revealed overexpression of the gene encoding frizzled homologue 10 (FZD10), a cell-surface receptor for molecules in the Wnt pathway, as a potential contributor to synovial sarcom...
-
Article
Expression of E-cadherin, cyclin D1, matrix metalloproteinase 9, and vascular endothelial growth factor in primary tumor of esophageal squamous cell carcinoma does not predict lymph node micrometastasis
In esophageal squamous cell carcinoma (ESCC), it has been reported that some genes are associated with lymph node (LN) metastasis. The intent of this study was to clarify the relation between LN micrometastasi...
